Stratus Medical Announces 2 New US Patents Issued for the Nimbus® RF Multitined Expandable Electrode

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

September 14, 2020

Stratus Medical, a company focused on advancing radiofrequency ablation (RFA) treatment for chronic pain, announced today that the United States Patent and Trademark Office has granted two new patents related to its Nimbus® RF Multitined Expandable Electrode. U.S. Patent No. 10,716,618, titled System and Methods for Tissue Ablation, issued on July 21, 2020, and U.S. Patent No. 10,736,688, titled Methods and Systems for Spinal Radio Frequency Neurotomy, issued on August 11, 2020.

Stratus Medical’s newest patents collectively contain 146 claims directed to radiofrequency systems. These claims provide broad protection for Stratus Medical’s Nimbus technology. Stratus Medical now holds two U.S. patents and 14 patents outside the U.S. on this technology, with two additional patent applications pending in the U.S. and 10 patent applications pending outside the U.S.

Bret Boudousquie, Stratus Medical CEO shared, “We see great opportunity to help patients suffering from chronic pain and improve quality of life as interventional pain medicine physicians expand their utilization of radiofrequency ablation (RFA) to treat pain in the spine, knee and sacroiliac joint. We are pleased to secure these new patents to protect our proprietary Nimbus technology as procedural protocols shift from traditional RFA needles to the Nimbus device, which provides a large volume lesion with the goal to improve patient outcomes. Nimbus is rapidly building market share due to its numerous clinical advantages over other large volume lesion RFA options, including faster procedure times and lower cost.”




Subscribe to Medical Device News Magazine

Related Articles